Icon is excited to announce the appointment of Dr
His accomplishments include serving as the Associate Director of the HMRI Clinical Trials Unit, Clinical Research Director for the NSW Health Statewide Biobank, and Chair of the
'Craig is an incredible win for Icon and his impressive reputation will no doubt bring new research opportunities and growth for our teams in
'We're really proud of our clinical leadership and our 300 plus doctor network committed to advancing cancer care and increasing access to new and emerging treatments.'
Throughout his career,
'Craig's dedication to research will confidently drive forward John's legacy and evolve Icon's research capabilities,' said Mark.
'We're the largest private provider of cancer clinical trials in
'Research is part of Icon's DNA and critical to delivering holistic cancer care. Craig's appointment marks the next chapter of growth and cements our position as leaders in oncology trials.'
'Icon has an incredibly impressive research and clinical governance framework with a proven ability to conduct an expansive trials program safely and efficiently,' said
'I'm looking forward to help lead Icon's research strategy alongside a well-established clinical team and provide clinical trial opportunities for our patients globally and improve quality of life for people, and families, and communities today and into the future.'
Icon delivers trials across Phase I - IV including an extensive Investigator Initiated Trials program, and has capability in medical oncology, haematology, radiation medicine, and theranostics.
Our research services here. Or view our 2022 Annual Research Report.
Contact:
Tel: (07) 3737 4500
(C) 2023 Electronic News Publishing, source